Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...

Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by ...

The Axsome drug, Auvelity, is already approved as a treatment for major depressive disorder. The preliminary results announced Monday are from two tests of the pill as a treatment for Alzheimer ...

Auvelity is an oral tablet that’s prescribed for depression. It’s a brand-name drug, and it’s not available as a generic medication. The cost of Auvelity can vary, but savings are available.

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on January 24.Invest with ...

Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones ...

Until then, the stock is expected to trade around the $80 range, with potential to rise to the $130 range upon approval of Auvelity. The firm's price target remains unchanged despite the recent ...

Until then, the stock is expected to trade around the $80 range, with potential to rise to the $130 range upon approval of Auvelity. The firm's price target remains unchanged despite the recent study ...